Oramed Pharmaceuticals

2:15 PM - 2:30 PM, Wednesday, June 5, 2019 ・ Theater 2
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
Ticker:
ORMP
Exchange:
nasdaq
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
oral insulin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
VP, Business Development
Oramed Pharmaceuticals